Year: 2018
Type: article
Abstract: The Next Phase of Human Gene-Therapy Oversight As gene therapy continues to change, so must the federal framework set up to oversee it. As new biotechnologies continue to emerge, the NIH and the FDA are proposing reductions in duplicative oversight and changes to the role of the Recombinant DNA Advisory Committee.
Source: New England Journal of Medicine
DOI: 10.1056/nejmp1810628
Authors: Francis S. Collins, Scott Gottlieb
Language: English
Subfield: Issues, ethics and legal aspects
Field: Nursing
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2885758238
